ACE and aplastic anemia: Due to no improvement in clinical symptoms and an increase in aplastic anemia, it is unpractical to choose an addition of NEP inhibitors (ecadotril) to standard therapies including angiotensin-converting enzyme (ACE) inhibitors [242].